The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks

Value in Health

Volumn 10, Issue 5, 2007, Pages 348-357

  Van Staa, Tjeerd Peter ^a,b,f   Kanis, John A ^c   Geusens, Piet ^d,e   Boonen, Annelies ^d   Leufkens, Hubert G M ^a   Cooper, Cyrus ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HASSELT UNIVERSITY   (Belgium)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cost effectiveness; Fracture; Osteoporosis; Postmenopausal women; Risedronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ELDERLY CARE; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SMOKING; THEORETICAL MODEL; VALIDATION PROCESS; VERTEBRA FRACTURE;

EID: 34748887123     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00188.x     Document Type: Article

References (23)

1. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002 360 : 711 15.
2. Zethraeus N, Ben Sedrine W, Caulin F, et al. Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 2002 13 : 841 57.
3. Stevenson M, Lloyd M, de Nigris E, et al. Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary and Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. Sheffield : National Institute for Clinical Excellence, 2005.
4. Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis. Bone 2002 31 : 26 31.
5. Walley T, Mantgani A. The UK general practice research database. Lancet 1997 350 : 1097 9.
6. van Staa TP, Geusens P, Pols HAP, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005 98 : 191 8.
7. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005 16 : 581 9.
8. van Staa TP, Leufkens HGM, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone 2002 31 : 508 14.
9. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002 17 : 716 24.
10. Kanis JA, Brazier J, Calvert N, et al. Treatment of established osteoporosis. Health Technol Assess 2002 6 : 49 52.
11. Cranney A, Guyatt G, Griffith L, et al. IX: summary meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002 23 : 570 8.
12. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998 316 : 736 41.
13. Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Rev Pharmacoeconomics Outcomes Res 2001 1 : 25 36.
14. Harrell HE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 : 361 87.
15. Stevenson M, Lloyd M, de Nigris E, et al. The Clinical Effectiveness and Cost-Effectiveness of Prevention and Treatment of Osteoporosis. Xxxxx : National Institute for Clinical Excellence, 2003. Available from URL: http://www.nice.org/page.aspx?o=115573 [Accessed May 10, 2004].
16. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998 280 : 2077 82.
17. Black DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value Health 2006 9 : 54 8.
18. Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 2005 16 : 6 14.
19. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001 344 : 333 40.
20. Green AD, Colon-Emeric CS, Bastian L, et al. Does this woman have osteoporosis? JAMA 2004 292 : 2890 900.
21. Geusens P, Hochberg MC, van der Voort DJ, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc 2002 77 : 629 37.
22. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003 32 : 468 73.
23. Cooper C, Atkinson EJ, O'Fallon M, Melton LJ III. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992 7 : 221 7.